Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial
- 28 March 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 395 (10234), 1444-1451
- https://doi.org/10.1016/s0140-6736(20)30554-7
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (TTR 219)
- Medtronic
- U.S. Food and Drug Administration
This publication has 26 references indexed in Scilit:
- The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medicationsAmerican Heart Journal, 2016
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysisThe Lancet, 2015
- Predictors of blood pressure response in the SYMPLICITY HTN-3 trialEuropean Heart Journal, 2014
- Home Blood Pressure and Cardiovascular Outcomes in Patients During Antihypertensive TherapyHypertension, 2014
- Impact of Renal Denervation on 24-Hour Ambulatory Blood PressureJournal of the American College of Cardiology, 2014
- Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trialEuropean Heart Journal, 2014
- A Controlled Trial of Renal Denervation for Resistant HypertensionThe New England Journal of Medicine, 2014
- Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 studyThe Lancet, 2013
- Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort studyThe Lancet, 2009
- Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General PopulationCirculation, 2005